The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Venous thromboembolism in cancer patients: a population-based cohort study
Open accessAbstract
The incidence of venous thromboembolism (VTE) in cancer patients may have changed in the past decade, possibly due to novel cancer therapies, improved survival, and high-resolution imaging. Danish medical registries were used to identify 499 092 patients with a first-time cancer diagnosis between 1997 and 2017, who were matched to 1 497 276 comparison individuals without cancer from the general population. We computed cumulative incidences of VTE 6 and 12 months after the diagnosis/index date. Hazard ratios (HRs) were calculated using Cox regression. Risk factors were examined by computing subdistribution hazard ratios (SHRs) in a competing-risk analysis. Cumulative incidence of VTE 12 months after the cancer diagnosis/index date was 2.3% (95% confidence interval [CI], 2.2% to 2.3%) in the cancer cohort and 0.35% (95% CI, 0.34% to 0.36%) in the comparison cohort (HR, 8.5; 95% CI, 8.2-8.8). Important risk factors for cancer patients were prior VTE (SHR, 7.6; 95% CI, 7.2-8.0), distant metastasis (SHR, 3.2; 95% CI, 2.9-3.4), and use of chemotherapy (SHR, 3.4; 95% CI, 3.1-3.7), protein kinase inhibitors (SHR, 4.1; 95% CI, 3.4-4.9), antiangiogenic therapy (SHR, 4.4; 95% CI, 3.8-5.2), and immunotherapy (SHR, 3.6; 2.8-4.6). Twelve-month incidence in the cancer cohort increased from 1.0% (95% CI, 0.9% to 1.2%) in 1997 to 3.4% (95% CI, 2.9% to 4.0%) in 2017, which was paralleled by improved 12-month survival and increased use of computed tomography scans, chemotherapy, and targeted therapies. In conclusion, the risk of VTE in cancer patients is increasing steadily and is ninefold higher than in the general population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
The Danish National Patient Registry: a review of content, data quality, and research potential
Schmidt, M., Schmidt, S. A. J., Sandegaard, J. L., Ehrenstein, V., Pedersen, L., & Sørensen, H. T. (2015) · Clinical Epidemiology · doi:10.2147/clep.s91125 · Cited by 4,769
Self-citationThe Danish Civil Registration System as a tool in epidemiology
Schmidt, M., Pedersen, L., & Sørensen, H. T. (2014) · European Journal of Epidemiology · doi:10.1007/s10654-014-9930-3 · Cited by 3,441
Self-citationThromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy
KHORANA, A. A., FRANCIS, C. W., CULAKOVA, E., KUDERER, N. M., & LYMAN, G. H. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02374.x · Cited by 1,670
Prognosis of Cancers Associated with Venous Thromboembolism
Sørensen, H. T., Mellemkjær, L., Olsen, J. H., & Baron, J. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432504 · Cited by 1,628
Self-citationKey, N. S., Khorana, A. A., Kuderer, N. M., Bohlke, K., Lee, A. Y. Y., Arcelus, J. I., Wong, S. L., Balaban, E. P., Flowers, C. R., Francis, C. W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01461 · Cited by 1,504
A DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVES
JONCKHEERE, A. R. (1954) · Biometrika · doi:10.1093/biomet/41.1-2.133 · Cited by 1,500
Data Resource Profile: The Danish National Prescription Registry
Pottegård, A., Schmidt, S. A. J., Wallach-Kildemoes, H., Sørensen, H. T., Hallas, J., & Schmidt, M. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw213 · Cited by 1,431
Self-citationSchmidt, M., Schmidt, S. A. J., Adelborg, K., Sundbøll, J., Laugesen, K., Ehrenstein, V., & Sørensen, H. T. (2019) · Clinical Epidemiology · doi:10.2147/clep.s179083 · Cited by 1,379
Self-citationGjerstorff, M. L. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494810393562 · Cited by 1,351
Epidemiology of cancer-associated venous thrombosis
Timp, J. F., Braekkan, S. K., Versteeg, H. H., & Cannegieter, S. C. (2013) · Blood · doi:10.1182/blood-2013-04-460121 · Cited by 1,205
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., Marquis, K., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814468 · Cited by 852
Sundbøll, J., Adelborg, K., Munch, T., Frøslev, T., Sørensen, H. T., Bøtker, H. E., & Schmidt, M. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012832 · Cited by 834
Self-citationFrequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients
Khorana, A. A., Francis, C. W., Culakova, E., Kuderer, N. M., & Lyman, G. H. (2007) · Cancer · doi:10.1002/cncr.23062 · Cited by 781
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
Khorana, A. A., Soff, G. A., Kakkar, A. K., Vadhan-Raj, S., Riess, H., Wun, T., Streiff, M. B., Garcia, D. A., Liebman, H. A., Belani, C. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814630 · Cited by 719
Farge, D., Frere, C., Connors, J. M., Ay, C., Khorana, A. A., Munoz, A., Brenner, B., Kakkar, A., Rafii, H., Solymoss, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30336-5 · Cited by 651
Self-citationThe Risk of a Diagnosis of Cancer after Primary Deep Venous Thrombosis or Pulmonary Embolism
Sørensen, H. T., Mellemkjær, L., Steffensen, F. H., Olsen, J. H., & Nielsen, G. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804233381701 · Cited by 620
Self-citationShapiro, C. L. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1712502 · Cited by 608
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients
Gomez, M. L., Gomez‐Raposo, C., & Lobo Samper, F. (2008) · Cancer · doi:10.1002/cncr.23524 · Cited by 549
Venous thromboembolism and cancer
Baron, J. A., Gridley, G., Weiderpass, E., Nyren, O., & Linet, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10018-6 · Cited by 513
Walker, A. J., Card, T. R., West, J., Crooks, C., & Grainge, M. J. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.10.021 · Cited by 512
Quaresma, M., Coleman, M. P., & Rachet, B. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61396-9 · Cited by 461
Cronin-Fenton, D. P., Søndergaard, F., Pedersen, L. A., Fryzek, J. P., Cetin, K., Acquavella, J., Baron, J. A., & Sørensen, H. T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605883 · Cited by 372
Self-citationScreening for Occult Cancer in Unprovoked Venous Thromboembolism
Carrier, M., Lazo-Langner, A., Shivakumar, S., Tagalakis, V., Zarychanski, R., Solymoss, S., Routhier, N., Douketis, J., Danovitch, K., Lee, A. Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506623 · Cited by 300
Katholing, A., Rietbrock, S., Bamber, L., Martinez, C., & Cohen, A. T. (2017) · Thrombosis and Haemostasis · doi:10.1160/th15-08-0686 · Cited by 294
Incidence of Venous Thromboembolism in the Year Before the Diagnosis of Cancer in 528 693 Adults
White, R. H., Chew, H. K., Zhou, H., Parikh-Patel, A., Harris, D., Harvey, D., & Wun, T. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1782 · Cited by 231
van Es, N., Di Nisio, M., Cesarman, G., Kleinjan, A., Otten, H.-M., Mahé, I., Wilts, I. T., Twint, D. C., Porreca, E., Arrieta, O., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.169060 · Cited by 231
Self-citationCancer-Associated Venous Thromboembolic Disease, Version 1.2015
Streiff, M. B., Holmstrom, B., Ashrani, A., Bockenstedt, P. L., Chesney, C., Eby, C., Fanikos, J., Fenninger, R. B., Fogerty, A. E., Gao, S., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0133 · Cited by 218
Khorana, A. A., Dalal, Lin, & Connolly (2013) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s39964 · Cited by 140
Kraaijpoel, N., Bleker, S. M., Meyer, G., Mahé, I., Martín, A. J. M., Bertoletti, L., Rutten, A., Beyer‐Westendorf, J., Porreca, E., Boulon, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01977 · Cited by 120
Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer
Sørensen, H. T., Sværke, C., Farkas, D. K., Christiansen, C. F., Pedersen, L. H., Lash, T. L., Prandoni, P., & Baron, J. A. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.032 · Cited by 114
Self-citationLiu, C., Yang, M., Chiang, S.-C., Hsu, H., Hong, Y., Hsiao, L., Liu, H., Chiou, T.-J., Chen, P., Lee, T., et al. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-01-0010 · Cited by 113
What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patients’ Quality of Life?
Lloyd, A. J., Dewilde, S., Noble, S., Reimer, E., & Lee, A. Y. Y. (2017) · Value in Health · doi:10.1016/j.jval.2017.09.015 · Cited by 92
Adelborg, K., Corraini, P., Darvalics, B., Frederiksen, H., Ording, A. G., Horváth–Puhó, E., Rørth, M. R., & Sørensen, H. T. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14475 · Cited by 54
Self-citationClinical implications of incidental venous thromboembolism in cancer patients
Mulder, F. I., Nisio, M. D., Ay, C., Carrier, M., Bosch, F. T. M., Segers, A. E. M., Kraaijpoel, N., GROSSO, M. A., Zhang, G., Verhamme, P. B., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01697-2019 · Cited by 46
Self-citationExisting data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort
Jensvoll, H., Severinsen, M. T., Hammerstrøm, J., Brækkan, S. K., Kristensen, S. R., Cannegieter, S. C., Blix, K., Tjønneland, A. M., Rosendaal, F. R., Dziewiecka, O., et al. (2015) · Clinical Epidemiology · doi:10.2147/clep.s84279 · Cited by 30
Blix, K., Gran, O. V., Severinsen, M. T., Cannegieter, S. C., Jensvoll, H., Overvad, K., Hammerstrøm, J., Tjønneland, A. M., Næss, I. A., Brækkan, S. K., et al. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14130 · Cited by 26
Risk models in genetic epidemiology
Claus, E. B. (2000) · Statistical Methods in Medical Research · doi:10.1177/096228020000900605 · Cited by 13
Blix, K., Brækkan, S. K., le Cessie, S., Skjeldestad, F. E., Cannegieter, S. C., & Hansen, J. (2014) · European Journal of Epidemiology · doi:10.1007/s10654-014-9902-7 · Cited by 12
Cited by
Embracing cancer complexity: Hallmarks of systemic disease
Swanton, C., Bernard, E., Abbosh, C., André, F., Auwerx, J., Balmain, A., Bar-Sagi, D., Bernards, R., Bullman, S., DeGregori, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.009 · Cited by 540
Farge, D., Frere, C., Connors, J. M., Khorana, A. A., Kakkar, A., Ay, C., Muñoz, A., Brenner, B., Prata, P. H., Brilhante, D., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00160-7 · Cited by 486
Self-citationCancer-associated venous thromboembolism
Khorana, A. A., Mackman, N., Falanga, A., Pabinger, I., Noble, S., Ageno, W., Moik, F., & Lee, A. Y. Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00336-y · Cited by 470
Self-citationVenous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
Falanga, A., Ay, C., Di Nisio, M., Gerotziafas, G., Jara-Palomares, L., Langer, F., Lecumberri, R., Mandala, M., Maraveyas, A., Pabinger, I., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.014 · Cited by 413
Self-citationPastori, D., Cormaci, V. M., Marucci, S., Franchino, G., Del Sole, F., Capozza, A., Fallarino, A., Corso, C., Valeriani, E., Menichelli, D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043169 · Cited by 324
Metadata
- Authors
- Mulder, F. I., Horváth-Puhó, E., van Es, N., van Laarhoven, H. W. M., Pedersen, L., Moik, F., Ay, C., Büller, H. R., & Sørensen, H. T.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2021-04-08
- Volume
- 137
- Issue
- 14
- Pages
- 1959-1969
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3100796456
- Cited by
- 723
- References
- 40
- FWCI
- 35.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.